These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 30937954)

  • 21. Protein-Bound Solute Clearance During Hemodialysis.
    Gomółka M; Niemczyk L; Szamotulska K; Wyczałkowska-Tomasik A; Rymarz A; Smoszna J; Jasik M; Pączek L; Niemczyk S
    Adv Exp Med Biol; 2019; 1153():69-77. PubMed ID: 30689177
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tryptophan-Derived Uremic Toxins and Thrombosis in Chronic Kidney Disease.
    Addi T; Dou L; Burtey S
    Toxins (Basel); 2018 Oct; 10(10):. PubMed ID: 30322010
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Indocyanine green plasma disappearance rate. Marker of partial hepato-splanchnic ischemia].
    Thümer O; Hüttemann E; Sakka SG
    Anaesthesist; 2007 Apr; 56(4):339-44. PubMed ID: 17279343
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aryl Hydrocarbon Receptor and Uremic Toxins from the Gut Microbiota in Chronic Kidney Disease Patients: Is There a Relationship between Them?
    Brito JS; Borges NA; Anjos JSD; Nakao LS; Stockler-Pinto MB; Paiva BR; Cardoso-Weide LC; Cardozo LFMF; Mafra D
    Biochemistry; 2019 Apr; 58(15):2054-2060. PubMed ID: 30912928
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of the Gut Microbiome in Uremia: A Potential Therapeutic Target.
    Ramezani A; Massy ZA; Meijers B; Evenepoel P; Vanholder R; Raj DS
    Am J Kidney Dis; 2016 Mar; 67(3):483-98. PubMed ID: 26590448
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vasopressin-induced changes in splanchnic blood flow and hepatic and portal venous pressures in liver resection.
    Bown LS; Ricksten SE; Houltz E; Einarsson H; Söndergaard S; Rizell M; Lundin S
    Acta Anaesthesiol Scand; 2016 May; 60(5):607-15. PubMed ID: 26763649
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Portosystemic encephalopathy in a patient treated with peritoneal dialysis.
    Paraíso V; Francos M; Rodríguez-Berzosa F; Felipe C; López-Valdés E; Martín R; Blázquez J; Chacón C; Fidalgo A; Martín J
    Am J Kidney Dis; 2007 Jun; 49(6):854-8. PubMed ID: 17533029
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Splanchnic cortisol production in dogs occurs primarily in the liver: evidence for substantial hepatic specific 11beta hydroxysteroid dehydrogenase type 1 activity.
    Basu R; Edgerton DS; Singh RJ; Cherrington A; Rizza RA
    Diabetes; 2006 Nov; 55(11):3013-9. PubMed ID: 17065337
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gut Microbiome in Chronic Kidney Disease.
    Armani RG; Ramezani A; Yasir A; Sharama S; Canziani MEF; Raj DS
    Curr Hypertens Rep; 2017 Apr; 19(4):29. PubMed ID: 28343357
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mitochondria as a Source and a Target for Uremic Toxins.
    Popkov VA; Silachev DN; Zalevsky AO; Zorov DB; Plotnikov EY
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31242575
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Duplex ultrasound in diagnosis of visceral blood circulation].
    Sieber CC
    Ultraschall Med; 1994 Oct; 15(5):248-52. PubMed ID: 7801096
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Indoxyl sulfate - the uremic toxin linking hemostatic system disturbances with the prevalence of cardiovascular disease in patients with chronic kidney disease.
    Kamiński TW; Pawlak K; Karbowska M; Myśliwiec M; Pawlak D
    BMC Nephrol; 2017 Jan; 18(1):35. PubMed ID: 28122514
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The gut microbiota and its relationship with chronic kidney disease.
    Plata C; Cruz C; Cervantes LG; Ramírez V
    Int Urol Nephrol; 2019 Dec; 51(12):2209-2226. PubMed ID: 31576489
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Meal induced changes in hepatic and splanchnic circulation: a noninvasive Doppler study in normal humans.
    Dauzat M; Lafortune M; Patriquin H; Pomier-Layrargues G
    Eur J Appl Physiol Occup Physiol; 1994; 68(5):373-80. PubMed ID: 8076615
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Disposition and clinical implications of protein-bound uremic toxins.
    Jansen J; Jankowski J; Gajjala PR; Wetzels JFM; Masereeuw R
    Clin Sci (Lond); 2017 Jul; 131(14):1631-1647. PubMed ID: 28667064
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gut microbiota in chronic kidney disease.
    Cigarran Guldris S; González Parra E; Cases Amenós A
    Nefrologia; 2017; 37(1):9-19. PubMed ID: 27553986
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of prebiotic (fructooligosaccharide) on uremic toxins of chronic kidney disease patients: a randomized controlled trial.
    Ramos CI; Armani RG; Canziani MEF; Dalboni MA; Dolenga CJR; Nakao LS; Campbell KL; Cuppari L
    Nephrol Dial Transplant; 2019 Nov; 34(11):1876-1884. PubMed ID: 29939302
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vascular syndromes in liver cirrhosis.
    Shenoda B; Boselli J
    Clin J Gastroenterol; 2019 Oct; 12(5):387-397. PubMed ID: 30980261
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disturbance of hepatic and intestinal microcirculation in experimental liver cirrhosis.
    Maksan SM; Ryschich E; Ulger Z; Gebhard MM; Schmidt J
    World J Gastroenterol; 2005 Feb; 11(6):846-9. PubMed ID: 15682478
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of chronic endoscopic variceal sclerotherapy on systemic and splanchnic hemodynamics in patients with cirrhosis.
    Ota K; Shijo H; Kokawa H; Kubara K; Kim T; Akiyoshi N; Yokoyama M; Okumura M
    Intern Med; 1994 Dec; 33(12):745-51. PubMed ID: 7718954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.